Jeffrey Lawson
Fundador en InnAVasc Medical, Inc. .
Perfil
Jeffrey H.
Lawson is the founder of InnAVasc Medical, Inc. (founded in 2013) and holds the title of Director.
He is currently the Chief Executive Officer at VarmX BV (since 2023), Vice Chairman & Chief Surgical Officer at Humacyte Global, Inc. (since 2015), and Director at the Vascular Access Society of The Americas, Kidney Health Initiative, and Foundation For Women & Girls With Blood Disorders.
Dr. Lawson previously served as Director & Chief Surgical Officer at Humacyte, Inc. in 2021.
He obtained a doctorate degree from the University of Vermont College of Medicine in 1991.
Cargos activos de Jeffrey Lawson
| Empresas | Cargo | Inicio |
|---|---|---|
Humacyte Global, Inc.
 Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Director/Miembro de la Junta | 01/07/2018 |
InnAVasc Medical, Inc.
 InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Fundador | 13/05/2013 |
| Kidney Health Initiative | Director/Miembro de la Junta | - |
| Vascular Access Society of The Americas | Director/Miembro de la Junta | - |
| Foundation For Women & Girls With Blood Disorders | Director/Miembro de la Junta | - |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Director Ejecutivo | 12/10/2023 |
Antiguos cargos conocidos de Jeffrey Lawson.
| Empresas | Cargo | Fin |
|---|---|---|
| HUMACYTE, INC. | Director/Miembro de la Junta | 31/12/2021 |
Formación de Jeffrey Lawson.
| University of Vermont College of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| HUMACYTE, INC. | Health Technology |
| Empresas privadas | 6 |
|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Health Technology |
| Kidney Health Initiative | |
| Vascular Access Society of The Americas | |
| Foundation For Women & Girls With Blood Disorders | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
- Bolsa de valores
- Insiders
- Jeffrey Lawson
